Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review DOI Creative Commons

Theodore Piper,

Francesca Small,

Sam P. Brown

и другие.

Addiction, Год журнала: 2025, Номер unknown

Опубликована: Янв. 30, 2025

Abstract Background and aims This is the first systematic review of extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco (TUD) other substance disorders (SUD). We aimed to summarise evidence efficacy AUD, TUD, SUD; evaluate its quality; offer recommendations research. Methods was a prospectively registered narrative open‐label, randomised controlled trials (RCT), observational studies d‐lysergic acid diethylamide (LSD), mescaline, psilocybin, ayahuasca, ketamine, ibogaine 3,4‐methylenedioxymethamphetamine (MDMA). Eligible had SUD outcome measures including craving, use, relapse, remission. Study quality evaluated using Cochrane Collaboration Risk Bias (RoB), RoB in Non‐randomised Studies Interventions tool. Certainty RCTs judged Grading Recommendations, Assessment, Development, Evaluations (GRADE) Findings 37 (2035 participants) were reviewed: LSD (14; n = 1047); mescaline (1; 7); psilocybin (4; 135); ayahuasca (3; 101); ketamine (10; 579); (5; 166); MDMA 14). There no serious adverse events reported any study. A two‐centre, placebo‐controlled, phase 2 superiority RCT double‐blind, four‐arm, placebo‐controlled AUD yielded best efficacy. Progression support 3 secured from an open‐label study TUD nine cannabis disorder, cocaine opioid (all with high‐RoB low‐GRADE certainty). Conclusions Psilocybin‐assisted appears have among treatments alcohol, tobacco, disorders. Future research should report safety events; screen person‐level characteristics indicating that contraindicated; strive mitigate blinding participants interventions; factorial designs drug psychotherapy trials; build consensus field‐specific Core Outcome Set.

Язык: Английский

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review DOI
Joost J. Breeksema,

Bouwe Kuin,

Jeanine Kamphuis

и другие.

Journal of Psychopharmacology, Год журнала: 2022, Номер 36(10), С. 1100 - 1117

Опубликована: Авг. 26, 2022

Small-scale clinical studies with psychedelic drugs have shown promising results for the treatment of several mental disorders. Before psychedelics become registered medicines, it is important to know full range adverse events (AEs) making balanced decisions.To systematically review presence AEs during and after administration serotonergic 3,4-methyenedioxymethamphetamine (MDMA) in studies.We searched PubMed, PsycINFO, Embase, ClinicalTrials.gov trials since 2000 describing quantitative qualitative included 44 articles (34 + 10 qualitative), treatments MDMA (psilocybin, lysergic acid diethylamide, ayahuasca) 598 unique patients. In many studies, were not assessed. Despite this limitation, seemed be overall well tolerated. Nausea, headaches, anxiety commonly reported acute across diagnoses compounds. Late headaches MDMA), fatigue, low mood, (MDMA). One serious AE occurred (increase premature ventricular contractions requiring brief hospitalization); no other required medical intervention. Qualitative suggested that psychologically challenging experiences may also therapeutically beneficial. Except ayahuasca, a large proportion patients had prior experience before entering studies.AEs are poorly defined context probably underreported literature due study design (lack systematic assessment AEs) sample selection. Acute meaningful, but better understanding requires detailed reporting.

Язык: Английский

Процитировано

128
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions DOI Creative Commons
Mauro Cavarra, Alessandra Falzone, Johannes G. Ramaekers

и другие.

Frontiers in Psychology, Год журнала: 2022, Номер 13

Опубликована: Июнь 10, 2022

Modern clinical research on psychedelics is generating interesting outcomes in a wide array of conditions when psychedelic-assisted psychotherapy delivered to appropriately screened participants and controlled settings. Still, number patients relapse or are less responsive such treatments. Individual contextual factors (i.e., set setting) seem play role shaping the psychedelic experience determining outcomes. These findings, coupled with data from literature effectiveness psychotherapy, frame therapeutic context as potential moderator efficacy, highlighting need investigate how functionally employ environmental relational factors. In this review, we performed structured search through two databases PubMed/Medline Scopus) identify records studies which used described associated psychotherapeutic intervention. The aim construct picture what models currently adopted report their Ad-hoc adapted methods were identified. Common principles, points divergence future directions highlighted discussed special attention toward stance, degree directiveness suggestive effects information provided patients.

Язык: Английский

Процитировано

71
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis DOI

Yuan Yao,

Dan Guo,

Tangsheng Lu

и другие.

Psychiatry Research, Год журнала: 2024, Номер 335, С. 115886 - 115886

Опубликована: Март 28, 2024

Язык: Английский

Процитировано

25
MDMA and MDMA-Assisted Therapy DOI
Aaron Wolfgang, Gregory A. Fonzo, Joshua C. Gray

и другие.

American Journal of Psychiatry, Год журнала: 2025, Номер 182(1), С. 79 - 103

Опубликована: Янв. 1, 2025

MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as "Ecstasy" or "Molly," has been used since the 1970s both in recreational and therapeutic settings. The Food Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) a Breakthrough for posttraumatic stress disorder (PTSD) 2017, FDA is requiring an additional phase 3 trial after rejecting initial New Application 2024. Unlike other psychedelics, uniquely induces prosocial subjective effects of heightened trust self-compassion while maintaining ego functioning well cognitive perceptual lucidity. While use nonmedical settings may still cause harm, especially due to adulterants when without proper precautions, conclusions that can be drawn from studies are limited by many confounds. This limits extent which evidence related extrapolated use. A considerable body preliminary suggests MDMA-AT delivered controlled clinical setting safe efficacious treatment PTSD. After course involving three administrations supported psychotherapy, 67%-71% individuals with PTSD no longer meet diagnostic criteria versus 32%-48% placebo-assisted therapy, endure at long-term follow-up. review primarily aims distinguish nonclinical using pharmaceutical-grade further describes putative neurobiological mechanisms underlying its effects, MDMA-AT, considerations level public health policy, future research directions.

Язык: Английский

Процитировано

5
Mescaline: The forgotten psychedelic DOI Creative Commons
Ioanna A. Vamvakopoulou,

Kelly A.D. Narine,

Ian Campbell

и другие.

Neuropharmacology, Год журнала: 2022, Номер 222, С. 109294 - 109294

Опубликована: Окт. 14, 2022

Mescaline (3,4,5-trimethoxyphenethylamine) is one of the oldest hallucinogens, with evidence use dating back 5700 years. a naturally occurring alkaloid found in cacti, mainly peyote cactus (Lophophora williamsii) and cacti Echinopsis genus. Since prohibition psychoactive substances early 70s, research on mescaline other classical psychedelics has been limited.This article aims to review pharmacology behavioural effects mescaline, focusing preclinical clinical research.Mescaline serotonin 5HT2A/2C receptor agonist, its main hallucinogenic being mediated via 5HT2A agonist action. It also exerts binding at α1A/2A noradrenaline D1/2/3 dopamine receptors. Overall, anxiolytic-like animals increases prosocial behaviour, locomotion, response reactivity. In humans, can induce euphoria, hallucinations, improvements well-being mental health conditions, psychotomimetic naturalistic or religious setting.The pharmacological mechanisms are similar those psychedelics, like psilocybin lysergic acid diethylamide (LSD). appears be safe consume, most intoxications mild easily treatable. Improvement ability overcome alcoholism render potentially beneficial settings. This part Special Issue 'Psilocybin Research'.

Язык: Английский

Процитировано

65
Psilocybin and MDMA for the treatment of trauma-related psychopathology DOI Creative Commons
Catherine Bird, Nadav Liam Modlin, James Rucker

и другие.

International Review of Psychiatry, Год журнала: 2021, Номер 33(3), С. 229 - 249

Опубликована: Апрель 3, 2021

This review examines the role of trauma in psychiatric morbidity and analogous psychoneurobiological changes. Trauma is a necessary criterion for Post-Traumatic Stress Disorder (PTSD), however, history highly correlated with variety conditions. Some evidence suggests that Major Depressive (MDD) most common condition arises following trauma. Approximately 50% PTSD cases present co-morbid MDD. Overlapping symptomatology neurobiology between these conditions underlie debate over whether phenomena result from problematic nosology or comorbid MDD + distinct phenotype trauma-related psychopathology. Regardless, similar treatment approaches have been employed historically, varying success. The drug-assisted psychotherapy model, which combines pharmacological psychotherapeutic approaches, currently being trialled as novel approach psychiatry. Both psilocybin- 3,4-Methylenedioxymethamphetamine (MDMA)-assisted received Food Drug Administration 'breakthrough therapy' designation resistant PTSD, respectively. paper reviews therapeutic rationale both psilocybin MDMA treating PTSD.

Язык: Английский

Процитировано

63
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review DOI

Aryan Sarparast,

Kelan Thomas, Benjamin Malcolm

и другие.

Psychopharmacology, Год журнала: 2022, Номер 239(6), С. 1945 - 1976

Опубликована: Март 7, 2022

Язык: Английский

Процитировано

52
The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD DOI Creative Commons
Christopher R. Nicholas, Julie B. Wang, Allison R. Coker

и другие.

Drug and Alcohol Dependence, Год журнала: 2022, Номер 233, С. 109356 - 109356

Опубликована: Фев. 11, 2022

Post-traumatic stress disorder (PTSD) is commonly associated with alcohol and substance use disorders (ASUD). A randomized, placebo-controlled, phase 3 trial demonstrated the safety efficacy of MDMA-assisted therapy (MDMA-AT) for treatment severe PTSD. This analysis explores patterns in patients receiving MDMA-AT compared to placebo plus (Placebo+Therapy). Adult participants PTSD (n = 90) were randomized three blinded trauma-focused sessions either or Placebo+Therapy. Eligible met DSM-5 criteria could meet mild (current) moderate (early remission) cannabis disorder; other SUDs excluded. The current analyses examined outcomes on standardized measures hazardous (i.e., Alcohol Use Disorder Identification Test; AUDIT) drug Drug DUDIT) at baseline prior randomization study termination. There no group differences AUDIT DUDIT scores baseline. Compared Placebo+therapy, was a significantly greater reduction mean (SD) change (Δ −1.02 (3.52) as 0.40 (2.70), F (80, 1) 4.20, p 0.0436; Hedge's g= .45). Changes not different between groups. may also lead subclinical improvements use. does appear increase risk illicit These data provide preliminary evidence support development an integrated co-occurring ASUD.

Язык: Английский

Процитировано

42
Psychedelic therapy in the treatment of addiction: the past, present and future DOI Creative Commons
Rayyan Zafar,

Maxim Siegel,

Rebecca Harding

и другие.

Frontiers in Psychiatry, Год журнала: 2023, Номер 14

Опубликована: Июнь 12, 2023

Psychedelic therapy has witnessed a resurgence in interest the last decade from scientific and medical communities with evidence now building for its safety efficacy treating range of psychiatric disorders including addiction. In this review we will chart research investigating role these interventions individuals addiction beginning an overview current socioeconomic impact addiction, treatment options, outcomes. We start by examining historical studies first psychedelic era mid-late 1900s, followed available real-world gathered naturalistic, observational, survey-based studies. then cover modern-day clinical trials therapies first-in-human to phase II trials. Finally, provide different translational human neuropsychopharmacology techniques, functional magnetic resonance imaging (fMRI) positron emission tomography (PET), that can be applied foster mechanistic understanding therapeutic mechanisms. A more granular effects psychedelics facilitate optimisation drug development landscape, ultimately improve patient

Язык: Английский

Процитировано

38
Therapeutic mechanisms of psychedelics and entactogens DOI
Boris D. Heifets, David E. Olson

Neuropsychopharmacology, Год журнала: 2023, Номер 49(1), С. 104 - 118

Опубликована: Июль 24, 2023

Язык: Английский

Процитировано

29